Serum Insitute of India, the world’s largest maker of vaccines, said it has already produced 40 million doses of AstraZeneca’s potential COVID-19 vaccine. Novavax vaccine, another top candidate, to be produced soon, adding that the bulk of the drug has been received from the US company.
Pfizer says its vaccine shows 95% efficacy, plans to get emergency approval from FDA.
Post Graduate Institute of Medical Science, #Rohtak in #Haryana will start phase 3 of #Covid9 vaccine candidate Covaxin from November 20, the vice-chancellor of the institute said.
Third phase trial of Covaxin to start on 20 Nov. 200 volunteers to be administered the vaccine early to study its anti-bodies response. There’ll be 2 doses;2nd dose to be given 28 days after first dose. Expecting vaccine’s efficacy to be more than 90%: VC, PGI Rohtak, Haryana
Apart from traditional and various other local culture vaccine. More than 170 countries are in talks to participate in the #Covid19 Vaccines Global Access (Covax) Facility to speed vaccine development and secure doses for all countries and distribute them to the most high-risk segment of each population.”
India Protein-based COVID vaccine candidates more suitable for India as to maintain low minus 70 degree C is critical consideration for India is storage temperature and a protein-based preventive might therefore work best for the country.
Five vaccine candidates are currently undergoing clinical trials in India. These include three that are in advanced stages of trials — the Oxford-AstraZeneca candidate for which the Pune-based Serum Institute is conducting Phase 3 clinical trials, Bharat Biotech’s Covaxin which is also in Phase 3, and Russia’s Sputnik V which is expected to start Phase 2/3 trials next week.
The other two candidates are Cadila’s experimental vaccine that has almost completed Phase 2 and a candidate by Biological E that in Phase 1/2.
China has been focusing on developing five types of vaccines, and each method has at least one entering clinical trials. In total, 11 vaccine candidates are in different stages of testing, Yang said.
World Health Organisation (WHO) has said nine candidate vaccines, including two from China, are currently being evaluated for inclusion in the COVAX Facility. The COVAX is co-led by Gavi, an international vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO. Its aim is to accelerate the development and manufacture of vaccines.
China has roped in more than a dozen countries including Brazil to conduct the final phase trials of Chinese-made experimental COVID-19 vaccines and even started vaccinating thousands of its emergency workers, according to official media reports here.
There are currently 47 Vaccines in Phase trials and 155 Vaccines in Clinical trials. From 47, Front Runners are: -Pfizer/BioNtech RNA Vaccine Best in Safety standards till now (90%efficacy). Phase 3 trials almost done. Countries counting high on this. 2/n
AstraZeneca vaccine is in the most advanced stage of human testing in India, adding that the company along with the Indian Council of Medical Research (ICMR) will pursue “early availability” of the doses in India.
India also has at least two indigenously developed vaccine candidates, while Dr Reddy’s Labs is conducting a trial for Russia’s vaccine candidate.
American pharmaceutical company Pfizer announced on Wednesday that its COVID-19 vaccine has demonstrated 95 % efficacy in late trials.
The company also said that it wants the US Food and Drug Administration (FDA) to approve the vaccine on an emergency basis. The company had previously produced a vaccine which was 90% effective.
According to a statement issued on the company’s website, the vaccine which Pfizer has developed in collaboration with German company BioNTech SE turned out to be 95% effective against COVID-19, 28 days after its first dose was administered to volunteers.
The statement said that the companies expect to produce up to 50 million vaccine doses this year on a global level, adding that they would produce another 1.3 billion doses by the end of 2021.
Vaccine need final authorization from the US Food and Drug Administration for its efficacy and no side effects to be tested pre administering in mass scale.